Noxopharm Ltd (ASX: NOX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Noxopharm Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Noxopharm Ltd (ASX: NOX)
Latest News
Healthcare Shares
Here's why the Noxopharm (ASX:NOX) share price is flying 16% today
Share Gainers
Here's why the Noxopharm (ASX:NOX) share price is surging 6% higher
⏸️ ASX Shares
3 ASX Healthcare shares feeling a little under the weather
Share Market News
What is going with the Noxopharm (ASX:NOX) share price today?
Share Market News
Noxopharm (ASX:NOX) share price closes 21% higher after clinical milestone
Share Market News
Why the Noxopharm (ASX:NOX) share price is bouncing up today
Share Market News
Why the Noxopharm (ASX:NOX) share price is jumping 14% higher today
Share Gainers
Why the Noxopharm (ASX:NOX) share price surged 8% higher today
Share Market News
Noxopharm share price soars 12% higher on drug update
NOX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Noxopharm Ltd
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.
NOX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
28 Mar 2024 | $0.07 | $0.00 | 0.00% | 37,671 | $0.07 | $0.07 | $0.07 |
27 Mar 2024 | $0.07 | $0.00 | 0.00% | 28,433 | $0.07 | $0.07 | $0.07 |
26 Mar 2024 | $0.06 | $0.00 | 0.00% | 205,083 | $0.07 | $0.07 | $0.06 |
25 Mar 2024 | $0.07 | $-0.01 | -14.08% | 488,610 | $0.07 | $0.07 | $0.07 |
22 Mar 2024 | $0.07 | $0.00 | 0.00% | 327,691 | $0.07 | $0.07 | $0.07 |
21 Mar 2024 | $0.07 | $0.00 | 0.00% | 218,547 | $0.07 | $0.07 | $0.07 |
20 Mar 2024 | $0.07 | $0.00 | 0.00% | 71,735 | $0.07 | $0.07 | $0.07 |
19 Mar 2024 | $0.07 | $0.00 | 0.00% | 32,054 | $0.07 | $0.07 | $0.07 |
18 Mar 2024 | $0.07 | $0.00 | 0.00% | 21,810 | $0.07 | $0.07 | $0.07 |
15 Mar 2024 | $0.07 | $0.00 | 0.00% | 78,871 | $0.07 | $0.07 | $0.07 |
14 Mar 2024 | $0.07 | $0.00 | 0.00% | 3,546 | $0.07 | $0.07 | $0.07 |
13 Mar 2024 | $0.07 | $0.00 | 0.00% | 242,039 | $0.07 | $0.07 | $0.07 |
12 Mar 2024 | $0.07 | $0.00 | 0.00% | 63,007 | $0.07 | $0.07 | $0.07 |
11 Mar 2024 | $0.07 | $0.00 | 0.00% | 460,224 | $0.07 | $0.07 | $0.07 |
08 Mar 2024 | $0.07 | $0.00 | 0.00% | 342,763 | $0.07 | $0.07 | $0.07 |
07 Mar 2024 | $0.07 | $0.00 | 0.00% | 135,285 | $0.07 | $0.07 | $0.07 |
06 Mar 2024 | $0.07 | $0.00 | 0.00% | 206,637 | $0.07 | $0.07 | $0.07 |
05 Mar 2024 | $0.07 | $0.00 | 0.00% | 207,666 | $0.07 | $0.07 | $0.07 |
04 Mar 2024 | $0.08 | $-0.01 | -12.20% | 135,718 | $0.08 | $0.08 | $0.07 |
01 Mar 2024 | $0.08 | $0.00 | 0.00% | 163,251 | $0.08 | $0.09 | $0.08 |
29 Feb 2024 | $0.08 | $0.00 | 0.00% | 1,681,124 | $0.08 | $0.11 | $0.08 |
28 Feb 2024 | $0.08 | $0.02 | 33.33% | 414,111 | $0.06 | $0.08 | $0.06 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
15 Sep 2023 | Frederick (Fred) Bart | Buy | 880 | $30 |
On-market trade.
|
14 Sep 2023 | Frederick (Fred) Bart | Buy | 253,001 | $9,108 |
On-market trade.
|
30 Jun 2023 | Frederick (Fred) Bart | Buy | 135,281 | $5,681 |
On-market trade.
|
29 Jun 2023 | Frederick (Fred) Bart | Transfer | 3,080,189 | $170,950 |
Off-market transfer.
|
29 Jun 2023 | Frederick (Fred) Bart | Transfer | 3,080,189 | $170,950 |
Off-market transfer.
|
09 May 2023 | Frederick (Fred) Bart | Buy | 500,000 | $21,000 |
On-market trade.
|
04 May 2023 | Frederick (Fred) Bart | Buy | 1,000,000 | $50,000 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Frederick (Fred) Bart | Non-Executive DirectorNon-Executive Chairman | May 2020 |
Mr Bart was appointed the Managing Director of Textile Industries Australia In 1985,. The Group employed over 1,200 people and distributed product to many countries worldwide. The Company manufactured and distributed the majority of bed linen in Australia under brands like Sheridan and ACTIL. In 1989, Mr Bart established and chairs a number of private companies under the umbrella of the Bart Group which covered hotels, retail, commercial and residential land development and technologies which still continue to operate. The Group today employs in excess of 1,000 people and is active in many local and overseas markets. In 2013, Mr Bart became Director and majority shareholder of Immunovative Therapies Limited, a private Israeli company involved in the manufacture of vaccines for the treatment of certain forms of cancer. The Company has undertaken trials in both collateral and liver cancers. He is a member of Risk Committee.
|
Mr Peter Ashley Marks | Non-Executive DirectorNon-Executive Deputy Chairman | Mar 2016 |
Mr Marks has over 35 years of experience in corporate advisory and investment banking. Over the course of his career, he has specialised in capital raising IPO's, cross border capital raisings, M&A transactions, corporate underwriting and venture capital transactions for companies based in Australia, the US and Israel. He has been involved in a range of transactions with a focus in the life-sciences, biotechnology, medical technology and high tech as well as the mining sector. Peter has served as both an Executive and Non-Executive Director of a number of different entities, many of which have been listed on the ASX, Nasdaq and AIM markets. He is Chair of Risk Committee.
|
Mr Boris Patkin | Non-Executive Director | Mar 2020 |
Mr Patkin brings market knowledge, thorough research and years of experience in investment markets and business consulting. As a financial and investment advisor, Boris has an understanding of industry trends and has insight into domestic and international markets. He specialises in the reconstruction of companies, investments and in international trade and is also a business consultant in the medical and disruptive technology arena. He is currently a member of MeSAFAA and is a senior advisor with Morgans Financial Ltd. He is also non-executive chairman of Ausmon Resources Ltd - since 2014. He is member of Risk Committee.
|
Dr Gisela Mautner | Chief Executive OfficerManaging Director | Feb 2022 |
Dr Mautner has more than 20 years of experience in global pharmaceutical organisations, including operational, medical and scientific advisory roles across multiple therapeutic areas. During her career she held senior positions at global pharmaceutical companies like MSD (Merck), Bayer and Amgen in Germany as well as Australia.
|
Mr David James Franks | Company Secretary | Jan 2017 |
-
|
David James Franks | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Milligene Pty Ltd (The Ge and Pr Kelly Family A/C)(i) | 26,249,106 | 8.98% |
Mrs Eleanore Goodridge | 13,050,000 | 4.47% |
Milligene Pty Ltd (The Ge and Pr Kelly Family A/C)(ii) | 8,000,000 | 2.74% |
Citicorp Nominees | 6,751,024 | 2.31% |
Rgt Capital Fund No 5 (Noxo) Pty Ltd | 6,500,333 | 2.22% |
Mr Fred Bart | 5,618,651 | 1.92% |
Link Traders (Aust) Pty Ltd(i) | 5,545,298 | 1.90% |
Link Traders (Aust) Pty Ltd (ii) | 5,041,224 | 1.73% |
Kale Capital Corporation Limited | 4,997,437 | 1.71% |
Jamber Investments Pty Ltd (The Amber Schwarz Fam A/C) | 4,252,761 | 1.46% |
Rhlc Pty Limited (Rhlc S/F A/C) | 3,200,000 | 1.09% |
Mr Lizhong Yu | 2,918,000 | 1.00% |
Blackcourt (Nsw) Pty Limited (Lawsam Super Fund A/C) | 2,686,376 | 0.92% |
Mr Robert Thomas Lin | 2,500,000 | 0.86% |
Ogen Nominees Pty Ltd | 2,300,000 | 0.79% |
Halcyon Nominees Pty Ltd (Halcyon Super Fund A/C) | 2,000,000 | 0.68% |
Mrs Sophie Ethel Gelski | 1,942,424 | 0.66% |
Helium Management Pty Ltd (Helium S/F A/C) | 1,751,246 | 0.60% |
Mr Michael Shabat & Ms Meital Hana Shabat (M&M Shabat Super Fund A/C) | 1,702,824 | 0.58% |
Berne No 132 Nominess Pty Ltd (331898 A/C) | 1,660,238 | 0.57% |